PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-6.78%
Revenue decline while Medical - Pharmaceuticals median is 0.08%. Seth Klarman would investigate if market share loss is temporary.
-7.09%
Cost reduction while Medical - Pharmaceuticals median is 0.25%. Seth Klarman would investigate competitive advantage potential.
-5.59%
Gross profit decline while Medical - Pharmaceuticals median is 2.75%. Seth Klarman would investigate competitive position.
1.27%
Margin change of 1.27% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.55%
Operating expenses reduction while Medical - Pharmaceuticals median is 0.78%. Seth Klarman would investigate advantages.
-5.97%
Total costs reduction while Medical - Pharmaceuticals median is 1.76%. Seth Klarman would investigate advantages.
-100.00%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
2.06%
D&A change of 2.06% versus flat Medical - Pharmaceuticals D&A. Walter Schloss would verify adequacy.
-18.12%
EBITDA decline while Medical - Pharmaceuticals median is 1.34%. Seth Klarman would investigate causes.
-12.16%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-24.32%
Operating income decline while Medical - Pharmaceuticals median is 1.04%. Seth Klarman would investigate causes.
-18.82%
Operating margin decline while Medical - Pharmaceuticals median is 0.64%. Seth Klarman would investigate causes.
26.39%
Other expenses growth while Medical - Pharmaceuticals reduces costs. Peter Lynch would examine differences.
-22.29%
Pre-tax income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-16.64%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-21.16%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-22.82%
Net income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-17.21%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-22.81%
EPS decline while Medical - Pharmaceuticals median is 4.58%. Seth Klarman would investigate causes.
-22.81%
Diluted EPS decline while Medical - Pharmaceuticals median is 4.58%. Seth Klarman would investigate causes.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.25%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.13%. Seth Klarman would investigate strategy.